The introduction of long-acting pre-exposure prophylaxis (PrEP) options such as injectable cabotegravir (CAB PrEP) and other methods in the development pipeline presents an opportunity to improve PrEP uptake and effective use, particularly among those at an increased risk for HIV. Long-acting PrEP has the potential to accelerate efforts to reduce HIV incidence in these populations as part of comprehensive prevention.
To ensure that new technologies are a transformative approach to HIV prevention for those at an increased risk for HIV, this document highlights considerations for program implementers, advocates, policymakers and other stakeholders as they roll out long-acting PrEP for those at an increased risk for HIV.